Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study looking at samples to predict how people with advanced kidney cancer will respond treatment (EuroTARGET)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study was done to gather information that may help doctors predict how people with kidney cancer will respond to treatment.
More about this trial
When this study was done, doctors often treated kidney cancer with one of a group of targeted cancer treatments called tyrosine kinase inhibitors (TKIs). This includes the drugs sunitinib, sorafenib and pazopanib.
But these treatments don’t work for everyone, and some people have more side effects than others. Some people need to take a lower dose or stop treatment altogether because of the side effects they are having.
Researchers wanted to see if there was a way to predict how well treatment will work, and who will have more side effects. They wanted to gather information from people having these treatments, to see if it could help.
The research team hoped to collect blood and tissue samples and look at how well people did after treatment. They planned to analyse the samples to find out more about people’s genetic material (DNA) and specific proteins in their blood.
The aim of this study was to collect information which may help predict how well TKIs work for people with advanced kidney cancer.
Summary of results
- 748 people who were recruited as part of this study
- 462 people who had already taken part in another trial looking at treatment for kidney cancer
- 713 people (78%) had sunitinib
- 166 people (18%) had pazopanib
- 41 people (4%) had sorafenib
- their age, gender and height
- when they were diagnosed
- the size of the cancer
- where in the body the cancer had spread
- which treatment they’d had
- how well treatment worked
- any side effects they’d had
How to join a clinical trial
Professor Tim Eisen
Cambridge University Hospitals NHS Foundation Trust
European Commission (Seventh Framework Programme)
NIHR Clinical Research Network: Cancer
University of Cambridge